PT 20

Drug Profile

PT 20

Alternative Names: Modified ferric oxide adipate - Shield therapeutics; PT-20

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator Medical Research Council
  • Developer Medical Research Council; Phosphate Therapeutics
  • Class Ferric compounds; Hyperphosphataemia therapies; Small molecules
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hyperphosphataemia

Most Recent Events

  • 27 Sep 2016 Phase-II development is ongoing in USA
  • 20 Sep 2016 PT 20 will be available for licensing as from 01 Jan 2017. http://www.shieldtherapeutics.com/investors/
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top